Report Sections

See All Reports

  • HP:0002355: Difficulty walking
  • Pneumonia (359) Respiratory tract infection (38) Neoplasm (36) Abnormality of the cardiovascular system (34) Diabetes mellitus (33) Depressivity (29) Acute kidney injury (27) Hypoxemia (26) Hypertension (24) Abnormal lung morphology (24) Thromboembolism (22) Anosmia (20) Myocardial infarction (20) Arthritis (19) Type II diabetes mellitus (18) Stroke (16) Pulmonary embolism (16) Mental deterioration (15) Abnormality of coagulation (15) Pulmonary fibrosis (15) Chronic pulmonary obstruction (15) Abnormality of the kidney (14) Autistic behavior (14) Rheumatoid arthritis (14) Leukemia (14) Interstitial pneumonitis (14) Pulmonary obstruction (14) Asthma (13) Chronic pain (13) Congestive heart failure (12) Deep venous thrombosis (12) Neoplasm of the lung (12) Autism (11) Obesity (11) Respiratory distress (11) Colitis (11) Ulcerative colitis (11) Crohn's disease (11) Type I diabetes mellitus (10) Abnormality of the liver (9) Coronary artery atherosclerosis (9) Inflammation of the large intestine (9) Pulmonary insufficiency (9) Chronic kidney disease (9) Myocarditis (9) Behavioral abnormality (8) Psychosis (8) Dementia (8) Alzheimer disease (8) Carcinoma (8) Low levels of vitamin D (8) Sepsis (8) Infertility (7) Peripheral arterial stenosis (7) Renal insufficiency (6) Lymphopenia (6) Dysphagia (6) Lymphoma (6) Systemic lupus erythematosus (6) Osteoarthritis (6) Breast carcinoma (6) Psoriasiform dermatitis (6) Abnormality of the gastrointestinal tract (6) Fatigue (6) Encephalopathy (5) Premature birth (5) Bronchiectasis (5) Difficulty walking (5) Gastroparesis (5) Immunodeficiency (5) Obstructive sleep apnea (5) Autoimmunity (5) Knee osteoarthritis (5) Sleep apnea (5) Prostate cancer (5) Allergy (5) Non-small cell lung carcinoma (5) Schizophrenia (5) Neoplasm of the large intestine (5) Seizure (4) Hepatic fibrosis (4) Cardiac arrest (4) Weight loss (4) Migraine (4) Pulmonary arterial hypertension (4) Abnormal intestine morphology (4) Neoplasm of the pancreas (4) Colon cancer (4) Malnutrition (4) Paroxysmal atrial fibrillation (4) Disseminated intravascular coagulation (4) Attention deficit hyperactivity disorder (4) Inflammatory abnormality of the skin (4) Neoplasm of head and neck (4) Endometriosis (4) Addictive behavior (4) Hypercoagulability (4) Insomnia (4) Obsessive-compulsive behavior (3) Eczema (3) Atopic dermatitis (3) Spastic diplegia (3) Abnormal heart morphology (3) Cardiomyopathy (3) Fever (3) Hypothermia (3) Headache (3) Celiac disease (3) Reduced factor VIII activity (3) Lymphoid leukemia (3) Renal cell carcinoma (3) Abnormal anterior horn cell morphology (3) Amyotrophic lateral sclerosis (3) Cystoid macular edema (3) Arrhythmia (3) Cutaneous melanoma (3) Pulmonary edema (3) Ovarian neoplasm (3) Neuroendocrine neoplasm (3) Hypogeusia (2) Hearing impairment (2) Abnormality of the eye (2) Visual impairment (2) Conjunctivitis (2) Cataract (2) Uveitis (2) Agoraphobia (2) Abnormality of the endocrine system (2) Abnormality of the skin (2) Jaundice (2) Lymphedema (2) Spasticity (2) Meningitis (2) Abnormal joint morphology (2) Hepatic steatosis (2) Hepatic failure (2) Tachycardia (2) Angina pectoris (2) Pancreatitis (2) Abnormality of blood and blood-forming tissues (2) Thrombocytopenia (2) Autoimmune thrombocytopenia (2) Gout (2) Diarrhea (2) Gastroesophageal reflux (2) Apnea (2) Neurodegeneration (2) Alopecia of scalp (2) Mutism (2) Transient ischemic attack (2) Hyperkinetic movements (2) Polyphagia (2) Hypotension (2) Atherosclerosis (2) Hypoventilation (2) Squamous cell carcinoma (2) Myelodysplasia (2) Back pain (2) Low back pain (2) Muscular dystrophy (2) Stillbirth (2) Acute myeloid leukemia (2) Lymphoproliferative disorder (2) Myeloproliferative disorder (2) Multiple myeloma (2) Intervertebral disc degeneration (2) Stridor (2) Postprandial hyperglycemia (2) Hemeralopia (2) Arteritis (2) Hepatitis (2) Glioblastoma multiforme (2) Cervix cancer (2) Small cell lung carcinoma (2) Endocarditis (2) Toxemia of pregnancy (2) Myositis (2) Mania (2) Urinary retention (1) Urinary incontinence (1) Nephritis (1) Menorrhagia (1) Xerostomia (1) Otitis media (1) Conductive hearing impairment (1) Amblyopia (1) Periodontitis (1) IgA deposition in the glomerulus (1) Enuresis (1) Hypoparathyroidism (1) Adrenal insufficiency (1) Hyperaldosteronism (1) Osteopenia (1) Urticaria (1) Angiokeratoma corporis diffusum (1) Cholecystitis (1) Keratoconjunctivitis (1) Intellectual disability (1) Hemiparesis (1) Polyneuropathy (1) Syncope (1) Cerebral hemorrhage (1) Hepatocellular carcinoma (1) Intrauterine growth retardation (1) Hoarse voice (1) Dysphonia (1) Weak voice (1) Sudden cardiac death (1) Aortic valve stenosis (1) Bradycardia (1) Torsade de pointes (1) Atrioventricular block (1) Premature rupture of membranes (1) Dehydration (1) Constipation (1) Anorexia (1) Esophageal varix (1) Chorea (1) Status epilepticus (1) Subarachnoid hemorrhage (1) Abnormality of the spinal cord (1) Memory impairment (1) Encephalitis (1) Spina bifida (1) Language impairment (1) Waddling gait (1) Increased intracranial pressure (1) Biliary cirrhosis (1) Dilatation (1) Osteomyelitis (1) Central apnea (1) Hypokalemia (1) Hyponatremia (1) Hyperphosphatemia (1) Skeletal muscle atrophy (1) Male infertility (1) Spondylolisthesis (1) Myalgia (1) Bruxism (1) Neonatal death (1) Increased body weight (1) Intermittent claudication (1) Thrombophlebitis (1) Chronic bronchitis (1) Ventricular tachycardia (1) Acute myelomonocytic leukemia (1) Dilatation of the cerebral artery (1) Coronary artery stenosis (1) Venous insufficiency (1) Chronic lymphatic leukemia (1) Abnormality of bone marrow cell morphology (1) Hypersensitivity pneumonitis (1) Intraalveolar phospholipid accumulation (1) Neoplasm of the genitourinary tract (1) Neoplasm of the skin (1) Female infertility (1) Benign prostatic hyperplasia (1) Hip osteoarthritis (1) Bladder neoplasm (1) Stomatitis (1) Uterine neoplasm (1) Intestinal atresia (1) Placental abruption (1) Sinus tachycardia (1) Bronchiolitis (1) Erythroid hypoplasia (1) Asterixis (1) Hodgkin lymphoma (1) B-cell lymphoma (1) Ciliary dyskinesia (1) Myeloid leukemia (1) Chronic myelomonocytic leukemia (1) Morphea (1) Bronchitis (1) Hypercapnia (1) Pain (1) Retinal vein occlusion (1) Vasovagal syncope (1) Heart block (1) Cough (1) Neonatal asphyxia (1) Dyspareunia (1) Heart murmur (1) Cardiogenic shock (1) Cholangitis (1) Cholangiocarcinoma (1) Vulvar neoplasm (1) Neonatal sepsis (1) Glue ear (1) Abnormality of movement (1) Subdural hemorrhage (1) Biliary tract neoplasm (1) Nasal polyposis (1) Eclampsia (1) Esophagitis (1) Vaginal neoplasm (1) Cellulitis (1) Angioedema (1) Self-injurious behavior (1) Gastrointestinal stroma tumor (1) Bulimia (1) Neoplasm of the rectum (1) Chest pain (1) Atelectasis (1) Lymphocytosis (1) Polymenorrhea (1)

    HP:0002355: Difficulty walking

    Developed by Shray Alag, The Harker School
    Sections: Correlations, Clinical Trials, and HPO

    Correlations computed by analyzing all clinical trials.

    Navigate: Clinical Trials and HPO


    Correlated Drug Terms (10)


    Name (Synonyms) Correlation
    drug711 CME (active control) Wiki 0.45
    drug3882 TEAM Wheels Wiki 0.45
    drug2148 Live Long Walk Strong rehabilitation program Wiki 0.45
    Name (Synonyms) Correlation
    drug1681 HIIT (intervention) Wiki 0.45
    drug1364 Electrotherapy group Wiki 0.45
    drug4090 Treatment group: will receive a combination of Nitazoxanide, Ribavirin and Ivermectin for a duration of seven days : Wiki 0.45
    drug1559 Flywheel exercise Wiki 0.45
    drug1171 Ddrops® products, 50,000 IU, Oral Wiki 0.45
    drug1746 Home exercise Wiki 0.32
    drug4253 Vitamin D3 Wiki 0.18

    Correlated MeSH Terms (7)


    Name (Synonyms) Correlation
    D051346 Mobility Limitation NIH 1.00
    D020370 Osteoarthritis, Knee NIH 0.20
    D010003 Osteoarthritis, NIH 0.18
    Name (Synonyms) Correlation
    D000073496 Frailty NIH 0.16
    D059350 Chronic Pain NIH 0.12
    D045169 Severe Acute Respiratory Syndrome NIH 0.02
    D018352 Coronavirus Infections NIH 0.02

    Correlated HPO Terms (3)


    Name (Synonyms) Correlation
    HP:0005086 Knee osteoarthritis HPO 0.20
    HP:0002758 Osteoarthritis HPO 0.18
    HP:0012532 Chronic pain HPO 0.12

    Clinical Trials

    Navigate: Correlations   HPO

    There are 5 clinical trials


    1 The Live Long Walk Strong Rehabilitation Program: What Features Improve Mobility Skills?

    This study is being performed to evaluate the efficacy of the Live Long Walk Strong rehabilitation program in Veterans 50 years and older. This study will also examine the features of the program that contribute to improved gait speed.

    NCT04026503
    Conditions
    1. Mobility Limitation
    Interventions
    1. Other: Live Long Walk Strong rehabilitation program
    MeSH:Mobility Limitation
    HPO:Difficulty walking

    Primary Outcomes

    Description: Gait speed change will be assessed within 2 weeks post intervention and then in 8 and 16 weeks of subsequent follow-up.

    Measure: Gait Speed

    Time: within 2 weeks, 8 weeks, 16 weeks
    2 Evaluation of a Peer-led eHealth Wheelchair Skills Training Program: Training to Enhance Adaptation and Management for Wheelchair Users

    The purpose of this study is to evaluate the effect of a 1-month, peer-led eHealth training program (TEAM Wheels) on satisfaction with activity participation and related rehabilitation outcomes among individuals transitioning to manual wheelchair use, compared with current wheelchair training practice. The primary objectives include: 1. Measuring the effect of TEAM Wheels on satisfaction with participation in important activities of life compared to current practice; 2. Measuring retention of participation benefits at 6-months post treatment. Secondary Objectives relate to additional rehabilitation Outcomes and include: 1. Comparing the effect of TEAM Wheels to current practice on wheelchair skills capacity and performance; wheelchair-specific self-efficacy; health-related quality of life; and objective measurement of wheelchair mobility. 2. Measuring retention of rehabilitation outcome benefits at 6-months post treatment.

    NCT04090177
    Conditions
    1. Mobility Limitation
    Interventions
    1. Behavioral: TEAM Wheels
    MeSH:Mobility Limitation
    HPO:Difficulty walking

    Primary Outcomes

    Description: WhOM has been found to be the only tool that includes activities selected and weighted by the user and featured participation in social roles. WhOM has been identified as the most client-centred and psychometrically robust tool among participation outcomes for wheelchair users. It is administered as a semi-structured interview. Respondents identify 10 activities (5 performed inside and 5 performed outside of the home), rating their satisfaction with performance on an 11-point scale (0-10) for each activity. The WhOM demonstrates good reliability (Test-retest ICC = 0.83-0.88; Inter-rater ICC = 0.90-0.91) and validity (correlations with LIFE-H: rs = 0.3-0.5) in use among individuals with spinal cord injury and older adults (Test-retest ICC = 0.77-1.00; correlation with QUEST rs = 0.36 -0.45).

    Measure: Satisfaction with Participation: Wheelchair Outcome Measure (WhOM)

    Time: Baseline

    Description: WhOM has been found to be the only tool that includes activities selected and weighted by the user and featured participation in social roles. WhOM has been identified as the most client-centred and psychometrically robust tool among participation outcomes for wheelchair users. It is administered as a semi-structured interview. Respondents identify 10 activities (5 performed inside and 5 performed outside of the home), rating their satisfaction with performance on an 11-point scale (0-10) for each activity. The WhOM demonstrates good reliability (Test-retest ICC = 0.83-0.88; Inter-rater ICC = 0.90-0.91) and validity (correlations with LIFE-H: rs = 0.3-0.5) in use among individuals with spinal cord injury and older adults (Test-retest ICC = 0.77-1.00; correlation with QUEST rs = 0.36 -0.45).

    Measure: Satisfaction with Participation: Wheelchair Outcome Measure (WhOM)

    Time: Post-Treatment (Week 7)

    Description: WhOM has been found to be the only tool that includes activities selected and weighted by the user and featured participation in social roles. WhOM has been identified as the most client-centred and psychometrically robust tool among participation outcomes for wheelchair users. It is administered as a semi-structured interview. Respondents identify 10 activities (5 performed inside and 5 performed outside of the home), rating their satisfaction with performance on an 11-point scale (0-10) for each activity. The WhOM demonstrates good reliability (Test-retest ICC = 0.83-0.88; Inter-rater ICC = 0.90-0.91) and validity (correlations with LIFE-H: rs = 0.3-0.5) in use among individuals with spinal cord injury and older adults (Test-retest ICC = 0.77-1.00; correlation with QUEST rs = 0.36 -0.45).

    Measure: Satisfaction with Participation: Wheelchair Outcome Measure (WhOM)

    Time: 6-Month Follow-up (Week 31)

    Secondary Outcomes

    Description: To address environmental barriers, MWC users must learn specific mobility skills such as managing inclines, thresholds, and doorways. This is of considerable importance since training also involves learning to recognize risks and limitations. WST-Q evaluates 34 discrete skills; respondents rate their capacity (i.e. ability) with each skill as well as performance frequency. Capacity is rated as Yes (2), Yes with difficulty (1), or No (0); performance is rated as Always (2), Sometimes (1), or Never (0). Total skill Capacity (0-100%) and Performance (0-100%) scores are calculated. The WST has demonstrated excellent reliability for test-retest (ICC=0.90), intra-rater (ICC=0.96), and inter-rater (ICC=0.97) administration.

    Measure: Wheelchair Skills Test - Questionnaire (WST-Q)

    Time: Baseline

    Description: To address environmental barriers, MWC users must learn specific mobility skills such as managing inclines, thresholds, and doorways. This is of considerable importance since training also involves learning to recognize risks and limitations. WST-Q evaluates 34 discrete skills; respondents rate their capacity (i.e. ability) with each skill as well as performance frequency. Capacity is rated as Yes (2), Yes with difficulty (1), or No (0); performance is rated as Always (2), Sometimes (1), or Never (0). Total skill Capacity (0-100%) and Performance (0-100%) scores are calculated. The WST has demonstrated excellent reliability for test-retest (ICC=0.90), intra-rater (ICC=0.96), and inter-rater (ICC=0.97) administration.

    Measure: Wheelchair Skills Test - Questionnaire (WST-Q)

    Time: Post-Treatment (Week 7)

    Description: To address environmental barriers, MWC users must learn specific mobility skills such as managing inclines, thresholds, and doorways. This is of considerable importance since training also involves learning to recognize risks and limitations. WST-Q evaluates 34 discrete skills; respondents rate their capacity (i.e. ability) with each skill as well as performance frequency. Capacity is rated as Yes (2), Yes with difficulty (1), or No (0); performance is rated as Always (2), Sometimes (1), or Never (0). Total skill Capacity (0-100%) and Performance (0-100%) scores are calculated. The WST has demonstrated excellent reliability for test-retest (ICC=0.90), intra-rater (ICC=0.96), and inter-rater (ICC=0.97) administration.

    Measure: Wheelchair Skills Test - Questionnaire (WST-Q)

    Time: 6-Month Follow-up (Week 31)

    Description: Self-efficacy has been identified as a key component in the performance of wheelchair mobility skills. Incorporating the principles of cognitive theory, including self-efficacy, can promote program adherence and skill acquisition. Preliminary research has suggested that standardized training can increase wheelchair confidence among older adults. WheelCon-SF is a self-report questionnaire with 21 statements related to confidence using a wheelchair in various activities and environments. Items are rated on a scale from 0 ("not confident") to 10 ("completely confident"), providing a total mean score (0-10).27 The WheelCon-SF is more responsive than the original 65-item version; a recent study reported high test-retest reliability (ICC=0.98) and internal consistency (Cronbach's alpha = 0.95).

    Measure: Wheelchair Use Confidence Scale-(WheelCon-SF)

    Time: Baseline

    Description: Self-efficacy has been identified as a key component in the performance of wheelchair mobility skills. Incorporating the principles of cognitive theory, including self-efficacy, can promote program adherence and skill acquisition. Preliminary research has suggested that standardized training can increase wheelchair confidence among older adults. WheelCon-SF is a self-report questionnaire with 21 statements related to confidence using a wheelchair in various activities and environments. Items are rated on a scale from 0 ("not confident") to 10 ("completely confident"), providing a total mean score (0-10).27 The WheelCon-SF is more responsive than the original 65-item version; a recent study reported high test-retest reliability (ICC=0.98) and internal consistency (Cronbach's alpha = 0.95).

    Measure: Wheelchair Use Confidence Scale-(WheelCon-SF)

    Time: Post-Treatment (Week 7)

    Description: Self-efficacy has been identified as a key component in the performance of wheelchair mobility skills. Incorporating the principles of cognitive theory, including self-efficacy, can promote program adherence and skill acquisition. Preliminary research has suggested that standardized training can increase wheelchair confidence among older adults. WheelCon-SF is a self-report questionnaire with 21 statements related to confidence using a wheelchair in various activities and environments. Items are rated on a scale from 0 ("not confident") to 10 ("completely confident"), providing a total mean score (0-10).27 The WheelCon-SF is more responsive than the original 65-item version; a recent study reported high test-retest reliability (ICC=0.98) and internal consistency (Cronbach's alpha = 0.95).

    Measure: Wheelchair Use Confidence Scale-(WheelCon-SF)

    Time: 6-Month Follow-up (Week 31)

    Description: Health utility measurement is useful when evaluating the impact of rehabilitation interventions. National guidelines for healthcare economic analyses strongly advocate the use of a validated measure of health-related quality of life (HRQL), which can be converted to quality-adjusted life years (QALY). HUI3 is a brief questionnaire that asks subjects about their health status. The multiple-attribute utility scale is scored from -0.36 to 1.00, with higher scores, reflected better health and quality of life. Acceptable test-retest reliability was found among patients recovering from hip fracture (ICC = 0.72) .

    Measure: Health Utilities Index Mark 3 (HUI3)

    Time: Baseline

    Description: Health utility measurement is useful when evaluating the impact of rehabilitation interventions. National guidelines for healthcare economic analyses strongly advocate the use of a validated measure of health-related quality of life (HRQL), which can be converted to quality-adjusted life years (QALY). HUI3 is a brief questionnaire that asks subjects about their health status. The multiple-attribute utility scale is scored from -0.36 to 1.00, with higher scores, reflected better health and quality of life. Acceptable test-retest reliability was found among patients recovering from hip fracture (ICC = 0.72) .

    Measure: Health Utilities Index Mark 3 (HUI3)

    Time: Post-Treatment (Week 7)

    Description: Health utility measurement is useful when evaluating the impact of rehabilitation interventions. National guidelines for healthcare economic analyses strongly advocate the use of a validated measure of health-related quality of life (HRQL), which can be converted to quality-adjusted life years (QALY). HUI3 is a brief questionnaire that asks subjects about their health status. The multiple-attribute utility scale is scored from -0.36 to 1.00, with higher scores, reflected better health and quality of life. Acceptable test-retest reliability was found among patients recovering from hip fracture (ICC = 0.72) .

    Measure: Health Utilities Index Mark 3 (HUI3)

    Time: 6-Month Follow-up (Week 31)

    Description: To triangulate measurement of improvement in mobility and community engagement, accelerometry data (ActigraphTM, Pensacola FL) will be used to objectively measure MWC activation over a 10-day period at baseline, post-treatment, and follow-up data collection points. The Actigraph is attached to a rear wheel on the MWC; a battery provides up to 14 days of passive data collection without impeding MWC operation. Data loggers have demonstrated valid and reliable measurement of MWC movement, with accuracy beyond 90%. A tri-axial accelerometer records acceleration forces during MWC use, downloadable as a .csv file. Algorithms developed by our team convert data into total and mean values of distance, speed, and 'bout' frequency (meaningful transitions between functional activities), parameters that reflect mobility patterns and activity of MWC users which we expect to change as a result of improvements in skill and participation.

    Measure: Objective Wheelchair Mobility

    Time: Baseline

    Description: To triangulate measurement of improvement in mobility and community engagement, accelerometry data (ActigraphTM, Pensacola FL) will be used to objectively measure MWC activation over a 10-day period at baseline, post-treatment, and follow-up data collection points. The Actigraph is attached to a rear wheel on the MWC; a battery provides up to 14 days of passive data collection without impeding MWC operation. Data loggers have demonstrated valid and reliable measurement of MWC movement, with accuracy beyond 90%. A tri-axial accelerometer records acceleration forces during MWC use, downloadable as a .csv file. Algorithms developed by our team convert data into total and mean values of distance, speed, and 'bout' frequency (meaningful transitions between functional activities), parameters that reflect mobility patterns and activity of MWC users which we expect to change as a result of improvements in skill and participation.

    Measure: Objective Wheelchair Mobility

    Time: 2-weeks

    Description: To triangulate measurement of improvement in mobility and community engagement, accelerometry data (ActigraphTM, Pensacola FL) will be used to objectively measure MWC activation over a 10-day period at baseline, post-treatment, and follow-up data collection points. The Actigraph is attached to a rear wheel on the MWC; a battery provides up to 14 days of passive data collection without impeding MWC operation. Data loggers have demonstrated valid and reliable measurement of MWC movement, with accuracy beyond 90%. A tri-axial accelerometer records acceleration forces during MWC use, downloadable as a .csv file. Algorithms developed by our team convert data into total and mean values of distance, speed, and 'bout' frequency (meaningful transitions between functional activities), parameters that reflect mobility patterns and activity of MWC users which we expect to change as a result of improvements in skill and participation.

    Measure: Objective Wheelchair Mobility

    Time: 6-Month Follow-up
    3 High-Intensity Exercise to Attenuate Limitations and Train Habits in Older Adults With HIV

    This is a multi-site, randomized, single-blind (researchers), active treatment concurrent control trial with individuals aged 50-80 living with HIV who experience fatigue and live a sedentary lifestyle. The overall goals of this proposal are to determine whether high-intensity interval training (HIIT) can overcome physical function impairments and increased fatigue (Aim 1) and impairments in mitochondrial bioenergetics of older people with HIV (PWH) to a greater extent than continuous moderate-intensity exercise (CME) (Aim 2). We further seek to determine whether a biobehavioral coaching intervention following either HIIT or CME can promote long-term adherence to physical activity (Aim 3), a crucial component of the sustainability of the intervention. This study will enroll 200 participants in Aurora, Colorado and Cleveland, Ohio, and includes 20 visits over a one-year period. Data collection will occur at each visit, with baseline data collected at the initial visit. A 3-month follow-up will be conducted over the phone from the date of the final visit.

    NCT04550676
    Conditions
    1. Hiv
    2. Fatigue
    3. Mobility Limitation
    Interventions
    1. Behavioral: HIIT (intervention)
    2. Behavioral: CME (active control)
    MeSH:Mobility Limitation
    HPO:Difficulty walking

    Primary Outcomes

    Description: 400-m walk time is a continuous measure of the total time required to complete a 400-m walking course. Lower values indicate a faster walking speed.

    Measure: Change in physical function

    Time: 0-16 weeks

    Secondary Outcomes

    Description: The Lee Fatigue Score measures severity of fatigue. Possible scores range from 0 to 10, with higher scores indicating a worse outcome.

    Measure: Change in fatigue

    Time: 0-16 weeks
    4 Investigation of the Effectiveness of a Structured Squat-based Program in Knee Osteoarthritis Rehabilitation

    The main purpose of the study is to examine the effect of squat-based exercise approach in individuals with knee osteoarthritis. The aim of this study is to compare effect to three groups (flywheel exercise group, electrotherapy modality group and home exercise group) and also decrease the pain, increase muscle strength, activation values and increase the functional level of individuals. Osteoarthritis is the most common rheumatological disease in the world that primarily results in progressive cartilage destruction. Changes occurring as a result of osteoarthritis are the main cause of disability and are most common in the knee joint. Osteoarthritis; problems such as pain, tenderness, joint stiffness, joint swelling, movement restriction, joint deformities, loss of muscle strength, decreased functional capacity and impaired quality of life are observed. The daily life activities of individuals with knee osteoarthritis are restricted by the problems of walking up and down stairs, getting out of the chair, standing, squatting, walking. Improving the symptoms of the disease is an important goal of the rehabilitation process of patients with knee osteoarthritis. In individuals with knee osteoarthritis, joint structure and deformation in cartilage also show loss of strength with muscles. Strengthening exercises have been used in patients with knee osteoarthritis for a long time. Squat exercise is a type of exercise that is widely used as a strengthening exercise.

    NCT04588558
    Conditions
    1. Osteoarthritis Knees Both
    2. Pain, Chronic
    3. Walking, Difficulty
    Interventions
    1. Device: Flywheel exercise
    2. Other: Home exercise
    3. Device: Electrotherapy group
    MeSH:Osteoarthritis Osteoarthritis, Knee Chronic Pain Mobility Limitation
    HPO:Chronic pain Difficulty walking Knee osteoarthritis Osteoarthritis

    Primary Outcomes

    Description: The primary outcome measures included the level of function determined by the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) . WOMAC is a specific, valid, reliable criterion for knee osteoarthritis and includes 24 questions under three subheadings: pain, stiffness and physical function. Each question was scored according to the Likert scale as 0 = none, 1 = mild, 2 = moderate, 3 = severe, 4 = very severe.

    Measure: Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC)

    Time: 10 minutes

    Secondary Outcomes

    Description: EMG-BF (Intelect Advanced Color Combo + EMG, Chattanooga Group, TN, USA) was used to evaluate muscle activation level. The screen scale was used as a visual feedback, as an increased or decreasing signal tone with varying muscle activity as sensory feedback. The undermentioned muscles will be evaluated in study, Rectus femoris Vastus lateralis Vastus medialis Biceps femoris Gastrocnemius

    Measure: EMG-BF

    Time: 10 minutes

    Description: A dynamometer was used to evaluate muscle strength. Muscle strength was evaluated in the following muscles, each measurement was made three times and the average was taken. M. Iliopsoas M. Gluteus Maximus M. Gluteus Medius M. Quadriceps Femoris Hamstring muscle group M. Gastrosoleus M. Tibialis Anterior

    Measure: Muscle strength

    Time: 10 minutes

    Description: The instrument that measures sensitivity to pain and gives a numerical value is called an algometer. In total, application was made at 4 different points. Medial point of heel - Right Medial point of heel - Left Medial point of knee-Right Medial point of knee-Left Measurements were made three times and averaged.

    Measure: Algometer

    Time: 5 minutes

    Description: Purpose and application of the test: The Visual Analog Scale (VAS) is used to convert some values that cannot be measured numerically into numericals. Two end definitions of the parameter to be evaluated are written on both ends of a 100 mm line and the patient is asked to indicate where his condition is appropriate by drawing a line or by placing a point or pointing on this line. Rest, activity and night were evaluated in three different time periods

    Measure: Visual Analog Scale (VAS) Evaluation

    Time: 5 minutes

    Description: To determine fall risk and measure the progress of balance, sit to stand and walking.The patient stands up upon therapist's command: walks 3 meters, turns around, walks back to the chair and sits down.

    Measure: Time up and go test

    Time: 20 seconds

    Description: The 30 Second Sit to Stand Test is also known as 30 second chair stand test ( 30CST), is for testing leg strength and endurance in older adults.The participant is encouraged to complete as many full stands as possible within 30 seconds. The participant is instructed to fully sit between each stand.

    Measure: 30 Seconds Sit To Stand Test

    Time: 30 Seconds

    Description: The individual is asked to climb and descend 7 times. The total time is recorded.

    Measure: Step test

    Time: 1 minute

    Description: Lower extremity joints and range of motion were evaluated. Hip Flexion Hip Extension Hip Internal Rotation Hip External Rotation Knee Flexion Knee Extension Ankle Plantar Flexion Ankle Dorsi Flexion

    Measure: goniometer

    Time: 10 minutes
    5 Functional Recovery of Older Hospitalised Patients With COVID-19: a Prospective and Retrospective Cohort Study Extension to the Coronavirus Registry (COREG)

    Older adults and those with chronic underlying health conditions are the most susceptible to COVID-19 and its complications. Although there has been a rapid response to studying the effects of COVID-19 in the acute stages, little is known about recovery over the longer-term. Older adults who survive the diseases are at risk of developing persistent mobility limitations due to extensive bed rest during hospitalization. For older patients and those with underlying frailty recovering from COVID-19, this could rapidly lead to significant physical deconditioning and rapid declines in mobility. Understanding the trajectory of functional recovery of older hospitalised patients with COVID-19 in the short- and long-term is critical to improving patient outcomes and informing health and rehabilitative interventions for survivors.

    NCT04602260
    Conditions
    1. Covid19
    2. Corona Virus Infection
    3. Mobility Limitation
    4. Frailty
    MeSH:Coronavirus Infections Severe Acute Respiratory Syndrome Frailty Mobility Limitation
    HPO:Difficulty walking

    Primary Outcomes

    Description: The AM-PAC is an activity limitation instrument based on the International Classification of Functioning, Disability and Health (ICF) that assesses 3 functional domains: basic mobility, daily activities and applied cognition.

    Measure: Change in Activity Measure for Post Acute Care (AM-PAC) Basic Mobility Inpatient Version

    Time: Admission to hospital ward (0-14 days post ward admission) and discharge from hospital (0-14 days post discharge or up to 6 months, whichever comes first)

    Description: The AM-PAC is an activity limitation instrument based on the International Classification of Functioning, Disability and Health (ICF) that assesses 3 functional domains: basic mobility, daily activities and applied cognition.

    Measure: Change in Activity Measure for Post Acute Care (AM-PAC) Basic Mobility Outpatient Version

    Time: Admission to hospital ward (0-14 days post ward admission, to capture pre-morbid function), and at 3,6,9 and 12-months post hospital discharge

    Description: The AM-PAC is an activity limitation instrument based on the International Classification of Functioning, Disability and Health (ICF) that assesses 3 functional domains: basic mobility, daily activities and applied cognition.

    Measure: Change in Activity Measure for Post Acute Care (AM-PAC) Applied Cognitive Inpatient Version

    Time: Admission to hospital ward (0-14 days post ward admission) and discharge from hospital (0-14 days post discharge or up to 6 months, whichever comes first)

    Description: The AM-PAC is an activity limitation instrument based on the International Classification of Functioning, Disability and Health (ICF) that assesses 3 functional domains: basic mobility, daily activities and applied cognition.

    Measure: Change in Activity Measure for Post Acute Care (AM-PAC) Daily Activity

    Time: 3,6,9 and 12-months post hospital discharge

    Secondary Outcomes

    Description: The SPPB combines the results of gait speed over 3 meters, the 5-repetition chair-stand, and a progressive balance test to assess lower extremity function.

    Measure: Change in Short Physical Performance Battery (SPPB)

    Time: 3,6,9 and 12-months post hospital discharge

    Description: The CFS is an interview-based scale wherein the assessor may ask the patient questions about things such as their independence or physical abilities to determine where the patient falls along the 9-point scale, from 1 (Very Fit) to 9 (Terminally Ill).

    Measure: Change in Clinical Frailty Scale (CFS) for participants over 60 years of age

    Time: Admission to hospital ward (0-14 days post ward admission, to capture pre-morbid function ), and at 3,6,9 and 12-months post hospital discharge

    Description: The Forced Expiratory Volume in 1 Second parameter measures the volume of air that was exhaled into the mouthpiece in the first second after a full inhalation as measured by spirometry.

    Measure: Change in Forced Expiratory Volume (FEV1)

    Time: 3,6,9 and 12-months post hospital discharge

    Description: The amount of air that can be forcibly exhaled from your lungs after taking the deepest breath possible, as measured by spirometry. FVC is the total amount of air exhaled during the FEV test.

    Measure: Change in Forced Vital Capacity (FVC)

    Time: 3,6,9 and 12-months post hospital discharge

    Description: The FEV1/FVC Ratio (FEV1%) parameter is calculated by dividing the measured FEV1 value by the measured FVC value.

    Measure: Change in Forced Expiratory Volume Percentage (FEV1%)

    Time: 3,6,9 and 12-months post hospital discharge

    Description: The BDI rates the severity of dyspnea at a single point in time (baseline) based on a 24-item interviewer administered rating scale.

    Measure: Baseline Dyspnea Index (BDI)

    Time: 3 months post hospital discharge

    Description: Measures changes in dyspnea severity from the baseline as established by the BDI.

    Measure: Change in Transition Dyspnea Index (TDI)

    Time: 6,9 and 12-months post hospital discharge

    Description: The PHQ-9 is a self-rating instrument for depression based on nine questions that the patient responds to by indicating how much they have been bothered by these symptoms over the last two weeks.

    Measure: Change in Patient Health Questionnaire - 9 (PHQ-9)

    Time: 3,6,9 and 12-months post hospital discharge

    Description: The FIM assesses the functional status of a person based on the level of assistance the person requires.

    Measure: Change in Functional Independence Measure (FIM)

    Time: 3 and 6 months post hospital discharge

    Description: The IES-R is a 22-item self-report measure that asks questions about subjective distress caused by traumatic events. Each item is rated on a 5-point scale, from 0 ("not at all") to 4 ("extremely").

    Measure: Change in Impact of Event Scale - Revised (IES-R)

    Time: 3,6,9 and 12-months post hospital discharge

    Description: The EQ-5D-5L is a generic and well-established instrument for describing health status or disease-specific outcome measures. It defines health in terms of five dimensions: Mobility, Self- Care, Usual Activities, Pain/Discomfort, and Anxiety/ Depression. The response options are of five levels, from no, slight, moderate, severe, to extreme problems

    Measure: Change in Health status (EQ-5D-5L)

    Time: 3,6,9 and 12-months post hospital discharge

    HPO Nodes


    HP:0002355: Difficulty walking
    Genes 292
    KCNA2 CHAT ERLIN1 TBC1D23 SLC18A3 ARL6IP1 SH3TC2 SCN8A USP9X ERCC8 NEB ATP13A2 SMO SACS EEF1A2 NTRK1 GAN GBA2 ACTL6B ARSI CYP27B1 HSPB3 CDK19 KLC2 B4GALNT1 NACC1 MED25 STRADA CYP27B1 SYNJ1 PNPLA2 GFPT1 LRP4 BVES PDGFB FKTN RYR1 ANO5 FBXO38 AP4E1 DES ERCC8 WWOX SYNGAP1 SORD PPP3CA FKRP ADCY5 ADAR KLHL41 SNAP25 TPM3 TTN SMARCE1 COASY HSPB1 ALG14 SGCD BAP1 SPG21 KY AP3B2 GRID2 CACNA1A ATP6 NECAP1 HPCA GABRB2 FGF12 ERCC6 PDK3 FOXG1 MECP2 GABRA2 HERC1 VCP MSTO1 GLE1 TAF1 ERCC4 KLHL41 KCND3 TPM2 TCAP TIA1 MATN3 TRAK1 DAG1 SCN3A CDK8 ELOVL5 ARSA POMT1 PARS2 NEB CRPPA DARS2 ABHD5 FLNC SLC5A7 DHTKD1 MYPN TGM6 TPM2 ACOX1 CYFIP2 REEP1 ACTA1 CACNA1B CAPN3 GJB1 POMT1 BICD2 VAMP1 MYF6 MATR3 ATP13A2 GMPPB GPAA1 UBA5 MORC2 ACTA1 SLC34A3 CHCHD10 CYP2R1 DPAGT1 DNA2 HK1 SLC13A5 SLC18A3 AP4M1 MSTO1 ERLIN2 GABRA5 MYOT VCP AGRN HK1 SLC25A19 C12ORF65 DDX6 ERCC6 WASHC5 MICU1 POMT1 SNAP25 AP4B1 SLC30A10 TERT IFIH1 SQSTM1 PIK3CA RTN2 WARS1 TK2 CRYAB PSAP SETX MYH7 DHDDS NKX6-2 GYG1 PLEKHG5 VAMP1 TPP1 DMD AP4S1 NF2 KLHL9 RNASEH2A TTN KBTBD13 VDR ALG2 PMP2 SUFU CIZ1 ATRX TTBK2 FKRP SLC5A7 GRIN2D NUS1 KCNA2 WDR48 ORAI1 BAP1 DNM1 NDUFS8 DALRD3 YWHAG IBA57 FKRP SMARCB1 PUS3 MICU1 POMT2 TRAPPC11 FA2H CPT1C CDKL5 CNKSR2 GABRB2 MORC2 RNASEH2C TRAPPC11 TRAPPC11 CAPN3 GABRG2 STUB1 SZT2 RNU12 FDX2 INTS1 SURF1 ARV1 ERCC8 STXBP1 FGF14 GALC TRNW FA2H DDHD1 PEX6 TGM6 HTT LRP12 SLC1A2 AKT1 PRX GOSR2 C19ORF12 NOP56 CPT1C GJC2 WARS2 TREX1 SLC30A9 CLTC ASAH1 PNPLA2 ASAH1 C12ORF65 SLC2A3 MYO9A EIF2S3 KCNC3 ERCC1 MTMR14 RSPRY1 ERLIN1 TRAF7 NTRK2 RAB11B RNASEH2B KCNB1 ATP7B GPT2 SPART DNM1L DNM1 HACE1 DNM2 ATP6V1A ALG14 NKX2-1 SGCB BIN1 NUBPL MARCHF6 RARS1 DYSF FHL1 PGAP1 FLRT1 HCN1 SYT2 SAMHD1 ERCC6 TPM3 PYCR2 CAPN1 SLC25A1 TIA1 AARS1 CCN6 SLC52A2 SBF2 ARL6IP1 MFN2 CYP2R1 COL13A1
    Protein Mutations 0
    SNP 0

    HPO

    Alphabetical listing of all HPO terms. Navigate: Correlations   Clinical Trials


    HPO Nodes


    HP:0002355: Difficulty walking
    Genes 292
    KCNA2 CHAT ERLIN1 TBC1D23 SLC18A3 ARL6IP1 SH3TC2 SCN8A USP9X ERCC8 NEB ATP13A2 SMO SACS EEF1A2 NTRK1 GAN GBA2 ACTL6B ARSI CYP27B1 HSPB3 CDK19 KLC2 B4GALNT1 NACC1 MED25 STRADA CYP27B1 SYNJ1 PNPLA2 GFPT1 LRP4 BVES PDGFB FKTN RYR1 ANO5 FBXO38 AP4E1 DES ERCC8 WWOX SYNGAP1 SORD PPP3CA FKRP ADCY5 ADAR KLHL41 SNAP25 TPM3 TTN SMARCE1 COASY HSPB1 ALG14 SGCD BAP1 SPG21 KY AP3B2 GRID2 CACNA1A ATP6 NECAP1 HPCA GABRB2 FGF12 ERCC6 PDK3 FOXG1 MECP2 GABRA2 HERC1 VCP MSTO1 GLE1 TAF1 ERCC4 KLHL41 KCND3 TPM2 TCAP TIA1 MATN3 TRAK1 DAG1 SCN3A CDK8 ELOVL5 ARSA POMT1 PARS2 NEB CRPPA DARS2 ABHD5 FLNC SLC5A7 DHTKD1 MYPN TGM6 TPM2 ACOX1 CYFIP2 REEP1 ACTA1 CACNA1B CAPN3 GJB1 POMT1 BICD2 VAMP1 MYF6 MATR3 ATP13A2 GMPPB GPAA1 UBA5 MORC2 ACTA1 SLC34A3 CHCHD10 CYP2R1 DPAGT1 DNA2 HK1 SLC13A5 SLC18A3 AP4M1 MSTO1 ERLIN2 GABRA5 MYOT VCP AGRN HK1 SLC25A19 C12ORF65 DDX6 ERCC6 WASHC5 MICU1 POMT1 SNAP25 AP4B1 SLC30A10 TERT IFIH1 SQSTM1 PIK3CA RTN2 WARS1 TK2 CRYAB PSAP SETX MYH7 DHDDS NKX6-2 GYG1 PLEKHG5 VAMP1 TPP1 DMD AP4S1 NF2 KLHL9 RNASEH2A TTN KBTBD13 VDR ALG2 PMP2 SUFU CIZ1 ATRX TTBK2 FKRP SLC5A7 GRIN2D NUS1 KCNA2 WDR48 ORAI1 BAP1 DNM1 NDUFS8 DALRD3 YWHAG IBA57 FKRP SMARCB1 PUS3 MICU1 POMT2 TRAPPC11 FA2H CPT1C CDKL5 CNKSR2 GABRB2 MORC2 RNASEH2C TRAPPC11 TRAPPC11 CAPN3 GABRG2 STUB1 SZT2 RNU12 FDX2 INTS1 SURF1 ARV1 ERCC8 STXBP1 FGF14 GALC TRNW FA2H DDHD1 PEX6 TGM6 HTT LRP12 SLC1A2 AKT1 PRX GOSR2 C19ORF12 NOP56 CPT1C GJC2 WARS2 TREX1 SLC30A9 CLTC ASAH1 PNPLA2 ASAH1 C12ORF65 SLC2A3 MYO9A EIF2S3 KCNC3 ERCC1 MTMR14 RSPRY1 ERLIN1 TRAF7 NTRK2 RAB11B RNASEH2B KCNB1 ATP7B GPT2 SPART DNM1L DNM1 HACE1 DNM2 ATP6V1A ALG14 NKX2-1 SGCB BIN1 NUBPL MARCHF6 RARS1 DYSF FHL1 PGAP1 FLRT1 HCN1 SYT2 SAMHD1 ERCC6 TPM3 PYCR2 CAPN1 SLC25A1 TIA1 AARS1 CCN6 SLC52A2 SBF2 ARL6IP1 MFN2 CYP2R1 COL13A1
    Protein Mutations 0
    SNP 0

    Reports

    Data processed on September 26, 2020.

    An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.

    Drug Reports   MeSH Reports   HPO Reports  

    Interventions

    4,180 reports on interventions/drugs

    MeSH

    691 reports on MeSH terms

    HPO

    263 reports on HPO terms

    All Terms

    Alphabetical index of all Terms

    Google Colab

    Python example via Google Colab Notebook